» Articles » PMID: 35125895

Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives

Overview
Publisher Dove Medical Press
Specialty Emergency Medicine
Date 2022 Feb 7
PMID 35125895
Authors
Affiliations
Soon will be listed here.
Abstract

Immune thrombocytopenia (ITP) is characterized by a platelet count less than 100 × 10^9/L without anemia or leukopenia. Patients with ITP may be asymptomatic, or they may have mild bleeding like petechiae, purpura, or epistaxis. In rare cases, they may present to the emergency department (ED) with life-threatening bleeding as a result of their thrombocytopenia. The emergency physician should thus be prepared to diagnose ITP and treat the bleeding that can result from it. The diagnosis of ITP requires excluding secondary causes of thrombocytopenia, and in the ED, the bare minimum workup for ITP includes a complete blood count and a peripheral blood smear. The peripheral blood smear should show a small number of large platelets with normal morphology, and there should not be an increased number of schistocytes. Many patients with ITP require no emergent treatment. However, if a patient with suspected ITP presents to the ED with critical hemorrhage, the emergency physician should initiate treatment with a platelet transfusion, corticosteroids, and intravenous immune globulin (IVIG) as soon as possible. For less severe bleeding, platelet transfusions are not recommended, and the treatment consists of corticosteroids by themselves or in conjunction with IVIG.

Citing Articles

Dengue Fever in an Adult Presenting as Immune Thrombocytopenic Purpura (ITP): A Case Report.

Sahoo D, Dey A, Bandyopadhyay T, Devi S, Dalei S Cureus. 2025; 16(12):e75124.

PMID: 39759744 PMC: 11700028. DOI: 10.7759/cureus.75124.


CpG can induce the proliferation and differentiation of B10 cells in the peripheral blood of children with immune thrombocytopenic purpura.

Gu S, Chen M, Xu W, Zhang H, Zhou H Ann Hematol. 2024; .

PMID: 39614925 DOI: 10.1007/s00277-024-06105-z.


The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.

Kos M, Tomaka P, Mertowska P, Mertowski S, Wojnicka J, Blazewicz A J Clin Med. 2024; 13(22).

PMID: 39597882 PMC: 11594473. DOI: 10.3390/jcm13226738.


[Immune thrombocytopenia: current diagnostics and therapy : The new 2023 expert report in brief].

Uzun G, Bakchoul T, Lengerke C, Moyses M Inn Med (Heidelb). 2024; 65(12):1225-1237.

PMID: 39589478 DOI: 10.1007/s00108-024-01815-y.


Ruptured Ovarian Cyst Leading to Massive Spontaneous Intraperitoneal Hemorrhage in Chronic Immune Thrombocytopenic Purpura (ITP): Successful Nonsurgical Intervention.

Gemnani R, Gaidhane S, Yelne P, Kadu A, Karwa V Cureus. 2024; 16(8):e66979.

PMID: 39280513 PMC: 11402497. DOI: 10.7759/cureus.66979.


References
1.
GARDNER F, Helmer 3rd R . Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA. 1980; 243(1):35-7. DOI: 10.1001/jama.243.1.35. View

2.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2008; 113(11):2386-93. DOI: 10.1182/blood-2008-07-162503. View

3.
McCullough J . Overview of platelet transfusion. Semin Hematol. 2010; 47(3):235-42. DOI: 10.1053/j.seminhematol.2010.04.001. View

4.
Mahevas M, Moulis G, Andres E, Riviere E, Garzaro M, Crickx E . Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020; 190(4):e224-e229. PMC: 7404899. DOI: 10.1111/bjh.17024. View

5.
Norgaard M, Severinsen M, Maegbaek M, Jensen A, Cha S, Sorensen H . Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2012; 159(1):109-11. DOI: 10.1111/j.1365-2141.2012.09231.x. View